Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data
Authors' conclusion
All scales effectively distinguished between low and high CV risk. PREVENT-CVD emerges as a valuable tool for assessing CV risk in CIRD patients.
Study context
- Population
- Patients with chronic inflammatory rheumatic diseases without prior cardiovascular (CV) events, 67 Spanish hospitals (2010–2012), CARMA project
- Participants
- 2,080 patients
- Exposure
- QRISK3 vs SCORE2 vs PREVENT-CVD vs PREVENT-ASCVD for predicting CV risk
- Outcome
- First CV event; performance of risk scales:
- AIC
- BIC
- Gönen
- Heller's K
- Follow-up
- 10 years
Methodological detailsmulticentre, 10-year follow-up, Cox regression adjusted for inflammatory disease
- Multicentre
- 10-year follow-up
- Cox regression adjusted for inflammatory disease
Main finding
As reported in the abstract
Association of risk scales with CV events
Hazard ratio (95% CI)
QRISK3
1.04(1.03–1.05)
SCORE2
1.13(1.11–1.16)
- First CV event in cohort
- 8.4% (174)
Observational data: associations, not effects.
Further findings
Calibration in RA patients (subgroup) · 10 years
- QRISK3 overestimated risk; PREVENT-CVD the only scale to perform reliably
Original publication
Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data. Rheumatology (Oxford). Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →